Key Milestones

In 2021, the U.S. Food and Drug Administration cleared the Investigational New Drug (IND) application for Poseida’ s first fully allogeneic CAR-T product candidate, P-BCMA-ALLO1 for the treatment of multiple myeloma. We presented strong CAR-T data in a solid tumor indication with our P-PSMA-101 program. In October 2021, we announced a strategic collaboration with Takeda focused on developing non-viral in vivo gene therapy programs utilizing our proprietary genetic engineering platform technologies.